Biogen (BIIB) P/E (2009 - 2026)
Biogen (BIIB) P/E from Jun 30, 2009 to Jul 21, 2026. The TTM Biogen (BIIB) P/E is 17.93. You can export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
P/E
Annual P/E change of Biogen (BIIB)
| Year | P/E | Change |
|---|---|---|
| 2026 | 17.93 | +20.49% |
| 2025 | 14.88 | -13.27% |
| 2024 | 17.16 | -6.11% |
| 2023 | 18.27 | +28.00% |
| 2022 | 14.27 | -26.27% |
| 2021 | 19.36 | +139.53% |
| 2020 | 8.08 | -18.26% |
| 2019 | 9.89 | -26.26% |
| 2018 | 13.41 | -24.32% |
| 2017 | 17.72 | +12.91% |
| 2016 | 15.69 | -22.19% |
| 2015 | 20.17 | -36.29% |
| 2014 | 31.66 | -13.84% |
| 2013 | 36.74 | +50.96% |
| 2012 | 24.34 | +8.69% |
| 2011 | 22.39 | +32.07% |
| 2010 | 16.95 | -53.86% |
| 2009 | 36.74 | N/A |
Comparison Biogen (BIIB) P/E with competitors
Biogen (BIIB) P/E is 17.93.
| Ticker | Name | P/E | Upside |
|---|---|---|---|
| GRFS | Grifols SA | 10.11 | -43.61% |
| PFE | Pfizer Inc | 11.65 | -35.00% |
| NVO | Novo Nordisk | 11.79 | -34.23% |
| GSK | GSK Plc | 12.10 | -32.49% |
| SNY | Sanofi | 12.12 | -32.37% |
| BMY | Bristol-Myers Squibb Company | 13.82 | -22.92% |
| OGN | Organon & Company | 14.33 | -20.09% |
| GILD | Gilead Sciences Inc | 17.75 | -1.02% |
| NVS | Novartis AG | 21.60 | +20.47% |
| JNJ | Johnson & Johnson | 22.09 | +23.20% |
| AMGN | AMGEN Inc | 24.75 | +38.06% |
| MRK | Merck & Co Inc | 26.93 | +50.20% |
| AZN | Astrazeneca plc | 28.44 | +58.65% |
| LLY | Lilly(Eli) & Company | 48.44 | +170.21% |
| ABBV | Abbvie Inc | 139.08 | +675.78% |